Literature DB >> 9310082

Calciotropic hormones and markers of bone remodeling in age-related (type II) femoral neck osteoporosis: alterations consistent with secondary hyperparathyroidism-induced bone resorption.

S Boonen1, P Broos, G Verbeke, J Aerssens, E Van Herck, I Jans, J Dequeker, R Bouillon.   

Abstract

BACKGROUND: Both a decrease in bone formation and the skeletal consequences of secondary hyperparathyroidism have been implied in the pathogenesis of age-related femoral neck osteoporosis. However, studies using biochemical indices of bone remodeling in hip fracture patients have yielded conflicting results. Similarly, secondary hyperparathyroidism has not been a consistent finding in this population. Some of these inconsistencies might reflect differences in the assays used as well as in the timing of the sampling. Moreover, measurements were mostly performed in a limited number of patients. In this regard, the aim of the present study was to analyze potential alterations in bone metabolism in a large population of elderly hip fracture patients.
METHODS: Circulating concentrations of 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)2D3], intact parathyroid hormone (PTH), and calcitonin were measured in 117 elderly women (within a few hours after sustaining a fracture of the proximal femur) and in 117 healthy age-matched controls. In addition, serum osteocalcin and urinary excretion of (deoxy)pyridinoline were determined as markers of bone formation and resorption, respectively.
RESULTS: Serum levels of 25(OH)D and 1,25(OH)2D3 were decreased in hip fracture patients. When correcting for differences in serum vitamin D binding protein, serum 25(OH)D was still significantly lower in patients than in controls, whereas serum 1,25(OH)2D3 was not. Moreover, 25(OH)D deficiency in hip fracture patients was associated with an increase in circulating PTH and urinary excretion of (deoxy)pyridinoline. Serum osteocalcin, on the other hand, was significantly decreased in fracture patients. There was no statistically significant difference in calcitonin.
CONCLUSION: These data suggest that there is reduced bone formation and increased bone resorption in patients with hip fracture. Although limited by its cross-sectional design, the present study emphasizes the role of secondary hyperparathyroidism-induced bone resorption in the pathogenesis of age-related osteoporosis, mainly due to a lack of 25(OH)D.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9310082     DOI: 10.1093/gerona/52a.5.m286

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  10 in total

Review 1.  Pathogenesis of postmenopausal osteoporosis.

Authors:  L G Raisz
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

2.  High prevalence of secondary hyperparathyroidism due to hypovitaminosis D in hospitalized elderly with and without hip fracture.

Authors:  A Giusti; A Barone; M Razzano; M Pizzonia; M Oliveri; E Palummeri; G Pioli
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

3.  The hormonal profile of hip fracture female patients differs from community-dwelling peers over a 1-year follow-up period.

Authors:  A R Cappola; W G Hawkes; N Blocher; J Yu-Yahiro; D Orwig; L Fredman; R R Miller; J M Guralnik; J Magaziner
Journal:  Osteoporos Int       Date:  2010-03-04       Impact factor: 4.507

4.  Calciotropic hormones and the risk of hip and nonspine fractures in older adults: the Health ABC Study.

Authors:  Kamil E Barbour; Denise K Houston; Steven R Cummings; Robert Boudreau; Tanushree Prasad; Yahtyng Sheu; Douglas C Bauer; Janet A Tooze; Stephen B Kritchevsky; Frances A Tylavsky; Tamara B Harris; Jane A Cauley
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

5.  Efficacy of optimization of vitamin D in preventing osteoporosis and osteoporotic fractures: A systematic review.

Authors:  Kazutoshi Nakamura; Masayuki Iki
Journal:  Environ Health Prev Med       Date:  2006-07       Impact factor: 3.674

Review 6.  Validated treatments and therapeutic perspectives regarding nutritherapy.

Authors:  H A Bischoff Ferrari
Journal:  J Nutr Health Aging       Date:  2009-10       Impact factor: 4.075

Review 7.  The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report.

Authors:  S Boonen; R Rizzoli; P J Meunier; M Stone; G Nuki; U Syversen; M Lehtonen-Veromaa; P Lips; O Johnell; J-Y Reginster
Journal:  Osteoporos Int       Date:  2004-07       Impact factor: 4.507

8.  Decrease in serum calcitriol (but not free 25-hydroxyvitamin D) concentration in hip fracture healing.

Authors:  J Vaculik; L Wenchich; M Bobelyak; K Pavelka; J J Stepan
Journal:  J Endocrinol Invest       Date:  2021-01-25       Impact factor: 4.256

9.  Hip fracture risk in relation to vitamin D supplementation and serum 25-hydroxyvitamin D levels: a systematic review and meta-analysis of randomised controlled trials and observational studies.

Authors:  Jeffrey K C Lai; Robyn M Lucas; Mark S Clements; Andrew W Roddam; Emily Banks
Journal:  BMC Public Health       Date:  2010-06-11       Impact factor: 3.295

10.  Bone mineral density and secondary hyperparathyroidism in pulmonary hypertension.

Authors:  Silvia Ulrich; Martin Hersberger; Manuel Fischler; Lars C Huber; Oliver Senn; Ursula Treder; Rudolf Speich; Christoph Schmid
Journal:  Open Respir Med J       Date:  2009-04-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.